China Medical System Holdings Limited (AIM:CMSH) is pleased to announce its participation in the review meeting of clinical research on treatment of Drug Induced Liver Injure(DILI) with Ursofalk (Ursodesoxycholic Acid， UDCA) which was hosted by CMS on 1 March 2009 in Shenzhen.
Nearly 20 experts from related research institutions including Chinese Society of Hepatology of CMA， involved hospitals， relative research centers， attended the meeting. Participating experts highly appreciated the efficacy and safety of UDCA in treating Drug Induced Liver Injury and brought up many valuable advices.There was also a special report about how to improve the reliability of diagnosis on DILI.
CMS‘ investment on DILI research won attendee‘s positive remarks. Success of this research provides powerful support to the deep promotion of Ursofalk on treating of DILI.